{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:54:49Z","timestamp":1784548489877,"version":"3.55.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The study was supported by a grant from the High Level Chinese Medical Hospital Promotion Project","award":["HLCMHPP2023027"],"award-info":[{"award-number":["HLCMHPP2023027"]}]},{"name":"The study was supported by a grant from the High Level Chinese Medical Hospital Promotion Project","award":["HLCMHPP2023088"],"award-info":[{"award-number":["HLCMHPP2023088"]}]},{"name":"Scientific Research Foundation for New recruits, China Academy of Chinese Medical Sciences","award":["ZZ16-XRZ-045"],"award-info":[{"award-number":["ZZ16-XRZ-045"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-06314-0","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:24:22Z","timestamp":1751415862000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real world pharmacovigilance study of antineoplastic drug related vitiligo risks"],"prefix":"10.1038","volume":"15","author":[{"given":"Yixuan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanzhang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongtao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingnan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanshuo","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"issue":"6","key":"6314_CR1","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1159\/000506103","volume":"236","author":"C Bergqvist","year":"2020","unstructured":"Bergqvist, C. & Ezzedine, K. Vitiligo: A review. Dermatology (Basel, Switzerland) 236(6), 571\u2013592. https:\/\/doi.org\/10.1159\/000506103 (2020).","journal-title":"Dermatology (Basel, Switzerland)"},{"issue":"3","key":"6314_CR2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jaad.2010.11.061","volume":"65","author":"A Alikhan","year":"2011","unstructured":"Alikhan, A., Felsten, L. M., Daly, M. & Petronic-Rosic, V. Vitiligo: A comprehensive overview Part I Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J. Am. Acad. Dermatol. 65(3), 473\u2013491. https:\/\/doi.org\/10.1016\/j.jaad.2010.11.061 (2011).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"6314_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1046\/j.1365-4362.2000.00880.x","volume":"39","author":"AM Boisseau-Garsaud","year":"2000","unstructured":"Boisseau-Garsaud, A. M. et al. Epidemiology of vitiligo in the French West Indies (Isle of Martinique). Int. J. Dermatol. 39(1), 18\u201320. https:\/\/doi.org\/10.1046\/j.1365-4362.2000.00880.x (2000).","journal-title":"Int. J. Dermatol."},{"issue":"1","key":"6314_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/archderm.113.1.47","volume":"113","author":"J Howitz","year":"1977","unstructured":"Howitz, J., Brodthagen, H., Schwartz, M. & Thomsen, K. Prevalence of vitiligo Epidemiological survey on the Isle of Bornholm, Denmark. Arch. Dermatol. 113(1), 47\u201352. https:\/\/doi.org\/10.1001\/archderm.113.1.47 (1977).","journal-title":"Arch. Dermatol."},{"issue":"10","key":"6314_CR5","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/j.1365-4632.2011.05377.x","volume":"51","author":"C Kr\u00fcger","year":"2012","unstructured":"Kr\u00fcger, C. & Schallreuter, K. U. A review of the worldwide prevalence of vitiligo in children\/adolescents and adults. Int. J. Dermatol. 51(10), 1206\u20131212. https:\/\/doi.org\/10.1111\/j.1365-4632.2011.05377.x (2012).","journal-title":"Int. J. Dermatol."},{"issue":"9","key":"6314_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163806","volume":"11","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y. et al. The prevalence of vitiligo: A meta-analysis. PLoS ONE 11(9), e0163806. https:\/\/doi.org\/10.1371\/journal.pone.0163806 (2016).","journal-title":"PLoS ONE"},{"issue":"1","key":"6314_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2016.10.048","volume":"77","author":"M Rodrigues","year":"2017","unstructured":"Rodrigues, M., Ezzedine, K., Hamzavi, I., Pandya, A. G. & Harris, J. E. New discoveries in the pathogenesis and classification of vitiligo. J. Am. Acad. Dermatol. 77(1), 1\u201313. https:\/\/doi.org\/10.1016\/j.jaad.2016.10.048 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"11","key":"6314_CR8","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/ng.3680","volume":"48","author":"Y Jin","year":"2016","unstructured":"Jin, Y. et al. Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants. Nat. Genet. 48(11), 1418\u20131424. https:\/\/doi.org\/10.1038\/ng.3680 (2016).","journal-title":"Nat. Genet."},{"issue":"2","key":"6314_CR9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.det.2016.11.013","volume":"35","author":"RA Spritz","year":"2017","unstructured":"Spritz, R. A. & Andersen, G. H. Genetics of vitiligo. Dermatol. Clin. 35(2), 245\u2013255. https:\/\/doi.org\/10.1016\/j.det.2016.11.013 (2017).","journal-title":"Dermatol. Clin."},{"issue":"2","key":"6314_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.det.2016.11.006","volume":"35","author":"JE Harris","year":"2017","unstructured":"Harris, J. E. Chemical-induced vitiligo. Dermatol. Clin. 35(2), 151\u2013161. https:\/\/doi.org\/10.1016\/j.det.2016.11.006 (2017).","journal-title":"Dermatol. Clin."},{"issue":"3","key":"6314_CR11","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1600-0536.1981.tb04598.x","volume":"7","author":"C Romaguera","year":"1981","unstructured":"Romaguera, C. & Grimalt, F. Occupational leukoderma and contact dermatitis from paratertiary-butylphenol. Contact Dermatitis 7(3), 159\u2013160. https:\/\/doi.org\/10.1111\/j.1600-0536.1981.tb04598.x (1981).","journal-title":"Contact Dermatitis"},{"issue":"5","key":"6314_CR12","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/pcmr.12269","volume":"27","author":"M Sasaki","year":"2014","unstructured":"Sasaki, M. et al. Rhododendrol, a depigmentation-inducing phenolic compound, exerts melanocyte cytotoxicity via a tyrosinase-dependent mechanism. Pigment Cell Melanoma Res. 27(5), 754\u2013763. https:\/\/doi.org\/10.1111\/pcmr.12269 (2014).","journal-title":"Pigment Cell Melanoma Res."},{"issue":"3","key":"6314_CR13","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jdermsci.2015.02.001","volume":"77","author":"Y Tokura","year":"2015","unstructured":"Tokura, Y. et al. Biochemical, cytological, and immunological mechanisms of rhododendrol-induced leukoderma. J. Dermatol. Sci. 77(3), 146\u2013149. https:\/\/doi.org\/10.1016\/j.jdermsci.2015.02.001 (2015).","journal-title":"J. Dermatol. Sci."},{"issue":"6","key":"6314_CR14","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/fcp.12558","volume":"34","author":"N Anthony","year":"2020","unstructured":"Anthony, N. et al. Drug-induced vitiligo: A case\/non-case study in Vigibase(\u00ae), the WHO pharmacovigilance database. Fundam. Clin. Pharmacol. 34(6), 736\u2013742. https:\/\/doi.org\/10.1111\/fcp.12558 (2020).","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"6","key":"6314_CR15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.62293","volume":"16","author":"AK Algethami","year":"2024","unstructured":"Algethami, A. K. et al. Palbociclib-induced vitiligo-like lesions: A report of a challenging case. Cureus 16(6), e62293. https:\/\/doi.org\/10.7759\/cureus.62293 (2024).","journal-title":"Cureus"},{"key":"6314_CR16","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae417","author":"J Huang","year":"2024","unstructured":"Huang, J., Su, A., Yang, J., Zhuang, W. & Li, Z. Post-marketing safety concerns of teprotumumab: A real-world pharmacovigilance assessment. J. Clin. Endocrinol. Metab. https:\/\/doi.org\/10.1210\/clinem\/dgae417 (2024).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"6314_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinane.2024.111509","volume":"97","author":"X Mao","year":"2024","unstructured":"Mao, X. et al. A pharmacovigilance study of FDA adverse events for sugammadex. J. Clin. Anesth. 97, 111509. https:\/\/doi.org\/10.1016\/j.jclinane.2024.111509 (2024).","journal-title":"J. Clin. Anesth."},{"issue":"2","key":"6314_CR18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/s0022-0981(00)00169-6","volume":"248","author":"TM Glasby","year":"2000","unstructured":"Glasby, T. M. Surface composition and orientation interact to affect subtidal epibiota. J. Exp. Mar. Biol. Ecol. 248(2), 177\u2013190. https:\/\/doi.org\/10.1016\/s0022-0981(00)00169-6 (2000).","journal-title":"J. Exp. Mar. Biol. Ecol."},{"issue":"21","key":"6314_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70379","volume":"13","author":"SR Miller","year":"2024","unstructured":"Miller, S. R. et al. Pan-cancer survival impact of immune checkpoint inhibitors in a national healthcare system. Cancer Med. 13(21), e70379. https:\/\/doi.org\/10.1002\/cam4.70379 (2024).","journal-title":"Cancer Med."},{"issue":"3","key":"6314_CR20","first-page":"186","volume":"4","author":"A Younis","year":"2024","unstructured":"Younis, A. & Gribben, J. Immune checkpoint inhibitors: Fundamental mechanisms. Curr. Status Future Dir. 4(3), 186\u2013210 (2024).","journal-title":"Curr. Status Future Dir."},{"key":"6314_CR21","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.2147\/dddt.S185896","volume":"14","author":"AL Blackmon","year":"2020","unstructured":"Blackmon, A. L. & Pinter-Brown, L. Spotlight on Mogamulizumab-Kpkc for use in adults with relapsed or refractory mycosis fungoides or s\u00e9zary syndrome: Efficacy safety, and patient selection. Drug Des. Dev. Therapy 14, 3747\u20133754. https:\/\/doi.org\/10.2147\/dddt.S185896 (2020).","journal-title":"Drug Des. Dev. Therapy"},{"key":"6314_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042203","author":"M Fern\u00e1ndez-Guarino","year":"2024","unstructured":"Fern\u00e1ndez-Guarino, M., Ortiz, P., Gallardo, F. & Llamas-Velasco, M. Clinical and real-world effectiveness of mogamulizumab: A narrative review. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms25042203 (2024).","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"6314_CR23","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1177\/08971900211009650","volume":"35","author":"SP Teo","year":"2022","unstructured":"Teo, S. P. Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273. J. Pharm. Pract. 35(6), 947\u2013951. https:\/\/doi.org\/10.1177\/08971900211009650 (2022).","journal-title":"J. Pharm. Pract."},{"issue":"1","key":"6314_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.86","volume":"2","author":"A Herzum","year":"2022","unstructured":"Herzum, A., Micalizzi, C., Molle, M. F. & Parodi, A. New-onset vitiligo following COVID-19 disease. Skin Health Dis. 2(1), e86. https:\/\/doi.org\/10.1002\/ski2.86 (2022).","journal-title":"Skin Health Dis."},{"issue":"10","key":"6314_CR25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.36120","volume":"6","author":"SH Lim","year":"2023","unstructured":"Lim, S. H. et al. Autoimmune and autoinflammatory connective tissue disorders following COVID-19. JAMA Netw. Open 6(10), e2336120. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.36120 (2023).","journal-title":"JAMA Netw. Open"},{"key":"6314_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10101647","author":"L Macca","year":"2022","unstructured":"Macca, L. et al. Vitiligo-like lesions and COVID-19: Case report and review of vaccination- and infection-associated vitiligo. Vaccines https:\/\/doi.org\/10.3390\/vaccines10101647 (2022).","journal-title":"Vaccines"},{"issue":"2","key":"6314_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2024.102961","volume":"55","author":"R Mormile","year":"2024","unstructured":"Mormile, R. De novo vitiligo following covid-19 infection and vaccination: A door open to future events?. Arch. Med. Res. 55(2), 102961. https:\/\/doi.org\/10.1016\/j.arcmed.2024.102961 (2024).","journal-title":"Arch. Med. Res."},{"key":"6314_CR28","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jdcr.2022.06.003","volume":"28","author":"R Singh","year":"2022","unstructured":"Singh, R., Cohen, J. L., Astudillo, M., Harris, J. E. & Freeman, E. E. Vitiligo of the arm after COVID-19 vaccination. JAAD Case Rep. 28, 142\u2013144. https:\/\/doi.org\/10.1016\/j.jdcr.2022.06.003 (2022).","journal-title":"JAAD Case Rep."},{"issue":"5","key":"6314_CR29","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1097\/01.lab.0000069521.42488.1b","volume":"83","author":"A Wa\u0144kowicz-Kali\u0144ska","year":"2003","unstructured":"Wa\u0144kowicz-Kali\u0144ska, A. et al. Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo. Lab. Investig. 83(5), 683\u2013695. https:\/\/doi.org\/10.1097\/01.lab.0000069521.42488.1b (2003).","journal-title":"Lab. Investig."},{"issue":"223","key":"6314_CR30","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1126\/scitranslmed.3007811","volume":"6","author":"M Rashighi","year":"2014","unstructured":"Rashighi, M. et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci. Transl. Med. 6(223), 223. https:\/\/doi.org\/10.1126\/scitranslmed.3007811 (2014).","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"6314_CR31","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","volume":"76","author":"W Damsky","year":"2017","unstructured":"Damsky, W. & King, B. A. JAK inhibitors in dermatology: The promise of a new drug class. J. Am. Acad. Dermatol. 76(4), 736\u2013744. https:\/\/doi.org\/10.1016\/j.jaad.2016.12.005 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"5","key":"6314_CR32","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1111\/bjd.15550","volume":"177","author":"C Jacquemin","year":"2017","unstructured":"Jacquemin, C. et al. Heat shock protein 70 potentiates interferon alpha production by plasmacytoid dendritic cells: relevance for cutaneous lupus and vitiligo pathogenesis. Br. J. Dermatol. 177(5), 1367\u20131375. https:\/\/doi.org\/10.1111\/bjd.15550 (2017).","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"6314_CR33","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.jid.2018.10.032","volume":"139","author":"JM Richmond","year":"2019","unstructured":"Richmond, J. M. et al. Resident memory and recirculating memory T cells cooperate to maintain disease in a mouse model of vitiligo. J. Investig. Dermatol. 139(4), 769\u2013778. https:\/\/doi.org\/10.1016\/j.jid.2018.10.032 (2019).","journal-title":"J. Investig. Dermatol."},{"issue":"3","key":"6314_CR34","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/1346-8138.15743","volume":"48","author":"C Bergqvist","year":"2021","unstructured":"Bergqvist, C. & Ezzedine, K. Vitiligo: A focus on pathogenesis and its therapeutic implications. J. Dermatol. 48(3), 252\u2013270. https:\/\/doi.org\/10.1111\/1346-8138.15743 (2021).","journal-title":"J. Dermatol."},{"issue":"3","key":"6314_CR35","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/1523-1747.ep12335801","volume":"109","author":"V Maresca","year":"1997","unstructured":"Maresca, V. et al. Increased sensitivity to peroxidative agents as a possible pathogenic factor of melanocyte damage in vitiligo. J. Investig. Dermatol. 109(3), 310\u2013313. https:\/\/doi.org\/10.1111\/1523-1747.ep12335801 (1997).","journal-title":"J. Investig. Dermatol."},{"issue":"12","key":"6314_CR36","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1038\/sj.jid.5700340","volume":"126","author":"DR Bickers","year":"2006","unstructured":"Bickers, D. R. & Athar, M. Oxidative stress in the pathogenesis of skin disease. J. Investig. Dermatol. 126(12), 2565\u20132575. https:\/\/doi.org\/10.1038\/sj.jid.5700340 (2006).","journal-title":"J. Investig. Dermatol."},{"issue":"2","key":"6314_CR37","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1684\/ejd.2021.4002","volume":"31","author":"AS Algarni","year":"2021","unstructured":"Algarni, A. S., Ram-Wolff, C., Bagot, M. & De Masson, A. Mogamulizumab-induced vitiligo in patients with S\u00e9zary syndrome: Three cases. Eur. J. Dermatol. EJD 31(2), 213\u2013216. https:\/\/doi.org\/10.1684\/ejd.2021.4002 (2021).","journal-title":"Eur. J. Dermatol. EJD"},{"key":"6314_CR38","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.ejca.2018.07.263","volume":"101","author":"M Bagot","year":"2018","unstructured":"Bagot, M., Ram-Wolff, C., Battustella, M. & De Masson, A. Long-term complete remission induced by mogamulizumab in a severe Sezary patient, together with five different possible auto-immune manifestations. Eur. J. Cancer 101, S22. https:\/\/doi.org\/10.1016\/j.ejca.2018.07.263 (2018).","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"6314_CR39","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/bjd.17320","volume":"180","author":"P Bonnet","year":"2019","unstructured":"Bonnet, P. et al. Association of autoimmunity and long-term complete remission in patients with S\u00e9zary syndrome treated with mogamulizumab. Br. J. Dermatol. 180(2), 419\u2013420. https:\/\/doi.org\/10.1111\/bjd.17320 (2019).","journal-title":"Br. J. Dermatol."},{"key":"6314_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.06.906","author":"L Serrano","year":"2022","unstructured":"Serrano, L., Wanat, K. A. & Chaney, K. 34539 Vitiligo associated with mogamulizumab. J. Am. Acad. Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2022.06.906 (2022).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"6314_CR41","doi-asserted-by":"publisher","first-page":"232","DOI":"10.2340\/00015555-3061","volume":"99","author":"P Iglesias","year":"2019","unstructured":"Iglesias, P. et al. Induced vitiligo due to talimogene laherparepvec injection for metastatic melanoma associated with long-term complete response. Acta Derm. Venereol. 99(2), 232\u2013233. https:\/\/doi.org\/10.2340\/00015555-3061 (2019).","journal-title":"Acta Derm. Venereol."},{"key":"6314_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10123154","author":"TJ Jeong","year":"2022","unstructured":"Jeong, T. J. et al. The high-resolution structure reveals remarkable similarity in PD-1 binding of cemiplimab and dostarlimab, the FDA-approved antibodies for cancer immunotherapy. Biomedicines https:\/\/doi.org\/10.3390\/biomedicines10123154 (2022).","journal-title":"Biomedicines"},{"issue":"2","key":"6314_CR43","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1053\/j.seminoncol.2017.06.002","volume":"44","author":"P Fessas","year":"2017","unstructured":"Fessas, P., Lee, H., Ikemizu, S. & Janowitz, T. A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin. Oncol. 44(2), 136\u2013140. https:\/\/doi.org\/10.1053\/j.seminoncol.2017.06.002 (2017).","journal-title":"Semin. Oncol."},{"issue":"9","key":"6314_CR44","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1001\/jamaoncol.2015.2274","volume":"1","author":"JA Lo","year":"2015","unstructured":"Lo, J. A., Fisher, D. E. & Flaherty, K. T. Prognostic significance of cutaneous adverse events associated with pembrolizumab therapy. JAMA Oncol. 1(9), 1340\u20131341. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2274 (2015).","journal-title":"JAMA Oncol."},{"key":"6314_CR45","doi-asserted-by":"publisher","first-page":"1573353","DOI":"10.3389\/fphar.2025.1573353","volume":"16","author":"TA Hammad","year":"2025","unstructured":"Hammad, T. A., Naylor, M., Ely, D. M. & Davies, S. Exploring the complexities of disproportionality analysis in pharmacovigilance: reflections on the READUS-PV guideline and a call to action. Front. Pharmacol. 16, 1573353. https:\/\/doi.org\/10.3389\/fphar.2025.1573353 (2025).","journal-title":"Front. Pharmacol."},{"issue":"1","key":"6314_CR46","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","volume":"152","author":"C Hua","year":"2016","unstructured":"Hua, C. et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 152(1), 45\u201351. https:\/\/doi.org\/10.1001\/jamadermatol.2015.2707 (2016).","journal-title":"JAMA Dermatol."},{"issue":"2","key":"6314_CR47","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/1346-8138.13520","volume":"44","author":"Y Nakamura","year":"2017","unstructured":"Nakamura, Y. et al. Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study. J. Dermatol. 44(2), 117\u2013122. https:\/\/doi.org\/10.1111\/1346-8138.13520 (2017).","journal-title":"J. Dermatol."},{"issue":"1","key":"6314_CR48","doi-asserted-by":"publisher","first-page":"00001","DOI":"10.2340\/00015555-3319","volume":"100","author":"A Ramondetta","year":"2020","unstructured":"Ramondetta, A. et al. Clinical and pathological relevance of drug-induced vitiligo in patients treated for metastatic melanoma with anti-PD1 or BRAF\/MEK inhibitors. Acta Derm. Venereol. 100(1), 00001. https:\/\/doi.org\/10.2340\/00015555-3319 (2020).","journal-title":"Acta Derm. Venereol."},{"issue":"2","key":"6314_CR49","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40264-019-00875-6","volume":"43","author":"S Babai","year":"2020","unstructured":"Babai, S., Voisin, A. L., Bertin, C., Gouverneur, A. & Le-Louet, H. Occurrences and outcomes of immune checkpoint inhibitors-induced vitiligo in cancer patients: A retrospective cohort study. Drug Saf. 43(2), 111\u2013117. https:\/\/doi.org\/10.1007\/s40264-019-00875-6 (2020).","journal-title":"Drug Saf."},{"issue":"3","key":"6314_CR50","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","volume":"19","author":"V Sibaud","year":"2018","unstructured":"Sibaud, V. Dermatologic reactions to immune checkpoint inhibitors\u202f: skin toxicities and immunotherapy. Am. J. Clin. Dermatol. 19(3), 345\u2013361. https:\/\/doi.org\/10.1007\/s40257-017-0336-3 (2018).","journal-title":"Am. J. Clin. Dermatol."},{"issue":"1","key":"6314_CR51","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/j.jaad.2017.08.028","volume":"78","author":"K Boniface","year":"2018","unstructured":"Boniface, K., Dutriaux, C., Prey, S., Taieb, A. & Seneschal, J. Vitiligo-like lesions in patients receiving anti-programmed cell death-1 therapies are distinct from spontaneously occurring active vitiligo. J. Am. Acad. Dermatol. 78(1), e17\u2013e18. https:\/\/doi.org\/10.1016\/j.jaad.2017.08.028 (2018).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"5","key":"6314_CR52","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2016.10.044","volume":"76","author":"M Larsabal","year":"2017","unstructured":"Larsabal, M. et al. Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo. J. Am. Acad. Dermatol. 76(5), 863\u2013870. https:\/\/doi.org\/10.1016\/j.jaad.2016.10.044 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"6314_CR53","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/1523-1747.ep12319752","volume":"109","author":"L Pulkkinen","year":"1997","unstructured":"Pulkkinen, L. et al. Predominance of the recurrent mutation R635X in the LAMB3 gene in European patients with Herlitz junctional epidermolysis bullosa has implications for mutation detection strategy. J. Investig. Dermatol. 109(2), 232\u2013237. https:\/\/doi.org\/10.1111\/1523-1747.ep12319752 (1997).","journal-title":"J. Investig. Dermatol."},{"issue":"3","key":"6314_CR54","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/j.1755-148X.2010.00703.x","volume":"23","author":"NA van Geel","year":"2010","unstructured":"van Geel, N. A. et al. First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi. Pigment Cell Melanoma Res. 23(3), 375\u2013384. https:\/\/doi.org\/10.1111\/j.1755-148X.2010.00703.x (2010).","journal-title":"Pigment Cell Melanoma Res."},{"issue":"3","key":"6314_CR55","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1046\/j.1523-1747.2003.12413.x","volume":"121","author":"RL Mandelcorn-Monson","year":"2003","unstructured":"Mandelcorn-Monson, R. L. et al. Cytotoxic T lymphocyte reactivity to gp100, MelanA\/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients. J. Investig. Dermatol. 121(3), 550\u2013556. https:\/\/doi.org\/10.1046\/j.1523-1747.2003.12413.x (2003).","journal-title":"J. Investig. Dermatol."},{"issue":"11","key":"6314_CR56","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1084\/jem.192.11.1637","volume":"192","author":"C Yee","year":"2000","unstructured":"Yee, C. et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: Direct evidence of t cell-mediated vitiligo. J. Exp. Med. 192(11), 1637\u20131644. https:\/\/doi.org\/10.1084\/jem.192.11.1637 (2000).","journal-title":"J. Exp. Med."},{"issue":"24","key":"6314_CR57","doi-asserted-by":"publisher","first-page":"4772","DOI":"10.1182\/blood-2012-04-427013","volume":"120","author":"EF Tewalt","year":"2012","unstructured":"Tewalt, E. F. et al. Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells. Blood 120(24), 4772\u20134782. https:\/\/doi.org\/10.1182\/blood-2012-04-427013 (2012).","journal-title":"Blood"},{"issue":"S11","key":"6314_CR58","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1002\/cncr.30444","volume":"123","author":"EH Byrne","year":"2017","unstructured":"Byrne, E. H. & Fisher, D. E. Immune and molecular correlates in melanoma treated with immune checkpoint blockade. Cancer 123(S11), 2143\u20132153. https:\/\/doi.org\/10.1002\/cncr.30444 (2017).","journal-title":"Cancer"},{"issue":"5","key":"6314_CR59","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","volume":"3","author":"EA Tivol","year":"1995","unstructured":"Tivol, E. A. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3(5), 541\u2013547. https:\/\/doi.org\/10.1016\/1074-7613(95)90125-6 (1995).","journal-title":"Immunity"},{"issue":"5256","key":"6314_CR60","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256), 1734\u20131736. https:\/\/doi.org\/10.1126\/science.271.5256.1734 (1996).","journal-title":"Science"},{"issue":"6230","key":"6314_CR61","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348(6230), 56\u201361. https:\/\/doi.org\/10.1126\/science.aaa8172 (2015).","journal-title":"Science"},{"issue":"2","key":"6314_CR62","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1158\/0008-5472.Can-17-1615","volume":"78","author":"X Mo","year":"2018","unstructured":"Mo, X. et al. Interferon-\u03b3 signaling in melanocytes and melanoma cells regulates expression of CTLA-4. Can. Res. 78(2), 436\u2013450. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-1615 (2018).","journal-title":"Can. Res."},{"issue":"10226","key":"6314_CR63","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/s0140-6736(20)30165-3","volume":"395","author":"LM Spring","year":"2020","unstructured":"Spring, L. M. et al. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet (London, England) 395(10226), 817\u2013827. https:\/\/doi.org\/10.1016\/s0140-6736(20)30165-3 (2020).","journal-title":"Lancet (London, England)"},{"issue":"1","key":"6314_CR64","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10549-020-05914-w","volume":"185","author":"P Sollena","year":"2021","unstructured":"Sollena, P. et al. Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors. Breast Cancer Res. Treat. 185(1), 247\u2013253. https:\/\/doi.org\/10.1007\/s10549-020-05914-w (2021).","journal-title":"Breast Cancer Res. Treat."},{"key":"6314_CR65","doi-asserted-by":"publisher","first-page":"1067264","DOI":"10.3389\/fonc.2023.1067264","volume":"13","author":"M Pasqualoni","year":"2023","unstructured":"Pasqualoni, M. et al. Case report: Vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response. Front. Oncol. 13, 1067264. https:\/\/doi.org\/10.3389\/fonc.2023.1067264 (2023).","journal-title":"Front. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06314-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06314-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06314-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:24:23Z","timestamp":1751415863000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06314-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6314"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-06314-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"23 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The patients\/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"22733"}}